Susquehanna International Group
EVGN icon

Susquehanna International Group’s Evogene EVGN Stock Holding History

Susquehanna International Group’s Portfolio EVGN Stock Details EVGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,030
Closed -$13K – 13163
2022
Q1 		$13K Sell
1,030
-2,830
-73% -$38.2K ﹤0.01% 12713
2021
Q4 		$63K Sell
3,860
-2,020
-34% -$45.8K ﹤0.01% 12434
2021
Q3 		$155K Buy
5,880
+1,980
+51% +$57.8K ﹤0.01% 11756
2021
Q2 		$133K Sell
3,900
-2,450
-39% -$96K ﹤0.01% 11925
2021
Q1 		$320K Buy
+6,350
New +$393K ﹤0.01% 10469

Other funds holding EVGN

SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RIG
Renaissance Investment Group Lenox, Massachusetts $508M AUM 30.51% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Susquehanna International Group's EVGN Position: Q3 2024 in Review

Susquehanna International Group sold out of Evogene (EVGN) in Q3 2024, closing a stake of 6,135 shares — an estimated $39.9K sold.

Susquehanna International Group first reported a position in EVGN in Q3 2020 and held it in 12 quarters. The position peaked at $287K in Q1 2021. 14 funds tracked by Wall St. Rank hold EVGN as of Q3 2024.

  • Susquehanna International Group reported no remaining Evogene position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 6,135 Evogene shares in Q3 2024, an estimated $39.9K.
  • Susquehanna International Group first reported a position in Evogene in Q3 2020 and held it in 12 quarters.
  • Susquehanna International Group's Evogene position peaked at $287K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Evogene as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.